3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
6
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Gliosarcoma
12
Glioblastoma
12
Sarcoma
10
Central Nervous System Neoplasms
8
Astrocytoma
8
Brain Neoplasms
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, Non-Hodgkin
6
Lymphoma, Mantle-Cell
6
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, Follicular
6
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Burkitt Lymphoma
6
Recurrence
5
Oligodendroglioma
5
Hodgkin Disease
5
Glioma
5
Dendritic Cell Sarcoma, Interdigitating
5
Leukemia, Myeloid, Acute
4
Leukemia, Myeloid, Accelerated Phase
4
Leukemia
4
Familial ependymoma
4
Ependymoma
4
Rhabdomyosarcoma
3
Primary Myelofibrosis
3
Osteosarcoma
3
Neoplasm Metastasis
3
Interventions
pembrolizumab
7
Cyclophosphamide
6
Nivolumab
4
fludarabine
3
spartalizumab
2
aldesleukin
2
Trastuzumab
2
Standard of Care
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Ipilimumab
2
Gemcitabine
2
zanidatamab
1
vocimagene amiretrorepvec
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tinostamustine
1
talazoparib
1
sarilumab
1
sargramostim
1
regorafenib
1
pexidartinib
1
pertuzumab
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
sargramostim
×
Sarcoma
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled